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Summary
Background WHO’s 2013 revisions to its Consolidated Guidelines on antiretroviral drugs recommend routine viral 
load monitoring, rather than clinical or immunological monitoring, as the preferred monitoring approach on the 
basis of clinical evidence. However, HIV programmes in resource-limited settings require guidance on the most cost-
eﬀ ective use of resources in view of other competing priorities such as expansion of antiretroviral therapy coverage. 
We assessed the cost-eﬀ ectiveness of alternative patient monitoring strategies.
Methods We evaluated a range of monitoring strategies, including clinical, CD4 cell count, and viral load monitoring, 
alone and together, at diﬀ erent frequencies and with diﬀ erent criteria for switching to second-line therapies. We used 
three independently constructed and validated models simultaneously. We estimated costs on the basis of resource 
use projected in the models and associated unit costs; we quantiﬁ ed impact as disability-adjusted life years (DALYs) 
averted. We compared alternatives using incremental cost-eﬀ ectiveness analysis.
Findings All models show that clinical monitoring delivers signiﬁ cant beneﬁ t compared with a hypothetical baseline 
scenario with no monitoring or switching. Regular CD4 cell count monitoring confers a beneﬁ t over clinical 
monitoring alone, at an incremental cost that makes it aﬀ ordable in more settings than viral load monitoring, which 
is currently more expensive. Viral load monitoring without CD4 cell count every 6–12 months provides the greatest 
reductions in morbidity and mortality, but incurs a high cost per DALY averted, resulting in lost opportunities to 
generate health gains if implemented instead of increasing antiretroviral therapy coverage or expanding antiretroviral 
therapy eligibility.
Interpretation The priority for HIV programmes should be to expand antiretroviral therapy coverage, ﬁ rstly at 
CD4 cell count lower than 350 cells per μL, and then at a CD4 cell count lower than 500 cells per μL, using lower-cost 
clinical or CD4 monitoring. At current costs, viral load monitoring should be considered only after high antiretroviral 
therapy coverage has been achieved. Point-of-care technologies and other factors reducing costs might make viral load 
monitoring more aﬀ ordable in future.
Funding Bill & Melinda Gates Foundation, WHO.
Introduction
The monitoring of patients on antiretroviral therapy is an 
important part of HIV care: it determines whether 
treatment is successful, or if a diﬀ erent drug regimen or 
improved adherence is required. Patients with treatment 
failure are more likely to have progressive disease and 
are at greater risk of dying, and patients with non-
suppressed virus are also at risk of developing resistance 
and transmitting HIV infections to others. Patients can 
be monitored and treatment failure can be deﬁ ned in 
many ways, in terms of the assays used (clinical 
monitoring with or without the measurement of 
CD4 count or plasma viral load), the frequency of checks 
(eg, every 3, 6, 12, or 36 months), and the decision rules 
applied for change of antiretroviral therapy based on 
clinical, CD4 count, or viral load criteria.
Every monitoring strategy carries diﬀ erent costs and 
health consequences. Determination of the cost 
eﬀ ectiveness of a given strategy requires decision makers 
to balance the gains in health it provides against the 
gains in health that could be achieved by allocating 
resources to other interventions. Health-economic 
analyses such as those presented here can provide 
guidance on how to measure and value health outcomes, 
and on how to allocate scarce resources to generate 
health gains at the population level.
Since 2006, WHO antiretroviral therapy guidelines 
have recommended a “public health approach” to 
antiretroviral therapy scale-up,1,2 based on standardised 
and simpliﬁ ed treatment and monitoring. This approach 
includes a common ﬁ rst-line regimen of a non-
nucleoside reverse transcriptase (NNRT) inhibitor plus 
two nucleoside reverse transcriptase (NRT) inhibitors, of 
which one should be either zidovudine or tenofovir, that 
can be delivered in decentralised settings. The 2010 
guidelines recommended that patients receive regular 
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clinical and immunological monitoring and, if feasible, 
virological monitoring and then switch to a diﬀ erent 
drug regimen (a second-line) once treatment failure is 
detected using any one of the following criteria: 
(1) clinical failure—ie, a new or recurrent WHO stage 
4 event; (2) immunological failure—ie, a fall of CD4 count 
to baseline (the start of treatment) or below, a 50% fall 
from an on-treatment peak value, or persistent CD4 levels 
below 100 cells per μL; and (3) virological failure—ie, 
plasma viral load higher than 5000 copies per mL while 
on treatment. These three deﬁ nitions can be detected 
with clinical monitoring, measurement of CD4 cell 
counts, and viral load monitoring, respectively.
The 2013 WHO Consolidated ARV Guidelines3 no 
longer recommend the use of a 50% fall from on-
treatment peak value for assessing immunological 
failure, and recommend viral load monitoring as the 
preferred approach to diagnose and conﬁ rm 
antiretroviral treatment failure in both adults and 
children, with failure deﬁ ned as two consecutive plasma 
viral loads above 1000 copies per mL within three 
months of one another after six or more months on 
treatment. However, countries still need to decide 
whether programmes currently using clinical or CD4 
monitoring should invest resources in upgrading clinics 
and laboratory infrastructure to use viral load 
monitoring.
Mathematical modelling and health economic 
evaluation allows for systematic, detailed consideration 
of the costs and health consequences of a broad repertoire 
of potential monitoring strategies over a range of 
timescales, and can therefore help inform countries’ 
decisions on how to invest limited resources. 
Consequently, we collated evidence from published 
modelling studies and undertook new analyses on the 
cost eﬀ ectiveness of alternative patient monitoring 
strategies. This study, which informed the WHO 
Guidelines, aims to identify appropriate monitoring 
strategies for programmes given their competing 
priorities and the wide variety of situations and resource 
constraints that they face.
Methods
Search criteria
To identify modelling groups for the WHO Guidelines 
process, we identiﬁ ed relevant modelling studies published 
between Sept 15, 2007, and Sept 15, 2012, through a search 
of PubMed/Medline and Google Scholar with search terms 
including “viral load monitoring”, “patient monitoring”, 
“cost-eﬀ ectiveness”, “mathematical modelling”, “anti-
retroviral therapy”, “modelling patient monitoring”, and 
“HIV treatment monitoring”. A list of studies reviewed 
(including some before Sept 15, 2007) is included in the 
appendix. We included models in the review if they 
assessed the eﬀ ect of patient monitoring strategies on 
health outcomes (treatment failure, viral loads, CD4 cell 
counts, clinical events or progression to AIDS) in a 
simulated population over time and also incorporated a 
cost-eﬀ ectiveness analysis. We contacted groups with 
publications meeting these criteria in the previous 5 years 
to participate in the WHO Guidelines process.
Models
Given the importance and complexity of the question, it 
was important not to base ﬁ ndings on a single 
mathematical model but rather to assemble a set of 
independently constructed and validated models. We 
contacted six modelling groups; three agreed to 
undertake new analyses for the project,4–8 whereas two9,10 
did not undertake new analyses but did contribute to the 
collective analysis presented here.
The mathematical models used were: the HIV 
Synthesis model (Phillips and colleagues,4,5 University 
College London, London, UK), Estill and colleagues6,7 
(University of Bern, Bern, Switzerland), and Braithwaite 
and colleagues8,11 (New York University, NY, USA). The 
Synthesis and Estill models are parameterised for a 
generic southern Africa setting, whereas the Braithwaite 
model is parameterised for an east Africa setting. We 
assumed that the clinical progression of HIV was 
similar in these populations. Table 1 summarises key 
features of the models. Our paper focuses on the 
implementation of these models for health-economic 
analysis; see the appendix for further details on the 
models themselves.
We applied country-speciﬁ c unit costs to each of these 
models to generate analyses for three countries 
representative of higher-resource, mid-resource, and 
lower-resource settings within southern Africa: South 
Africa, Zambia, and Malawi, respectively (appendix).
Choice of alternative monitoring strategies
We evaluated four sets of monitoring strategies, 
including clinical monitoring alone, CD4 cell count 
alone, routine viral load monitoring alone, at various 
thresholds; and two strategies comprising combinations 
of monitoring approaches. We also used a hypothetical 
scenario of no monitoring and no switching as a 
baseline comparator to establish the incremental costs 
Time 
horizon of 
simulation
Model tracks 
patients’ 
morbidity 
and mortality
Model tracks 
HIV 
transmission 
from patients 
to others
Modelled outcomes 
related to patients’ 
adherence to anti-
retroviral therapy
Models 
include 
acquired 
and trans-
mitted 
resistance
HIV Synthesis 15 years Yes Yes Yes Yes
Braithwaite and 
colleagues
20 years Yes No Yes Yes
Estill and colleagues 5 years Yes Not full trans-
mission model, 
but calculated 
expected trans-
missions based 
on viral loads
Incorporated in 
scenario analysis 
using failure rate as a 
proxy
No
Table 1: Features of the selected models 
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and eﬀ ects of each monitoring strategy in aﬀ ecting 
population health. These strategies indicate the 
spectrum of monitoring approaches used in high-
income, middle-income, and low-income settings, as 
well as potential new strategies. Not every model 
evaluated all strategies (table 2).
Costs and outcomes
We estimated costs from a health-sector perspective, in 
which only costs falling on the health system are 
included, and any wider, societal costs or beneﬁ ts are not 
included. We projected health-care resource use in the 
models (number of clinic visits, number and type of 
monitoring tests, ﬁ rst-line and second-line antiretroviral 
drugs prescribed, additional health-care use associated 
with disease progression) and applied associated unit 
costs representative of health-care delivery to estimate 
the total costs of strategies (all cost assumptions are 
listed in the appendix). Unit costs included personnel 
time, building costs, training, and facility management; 
we incorporated programmatic (above facility) costs on 
the basis of proportional mark-ups on unit costs of 
resource inputs.
We summarised the health eﬀ ects of the alternative 
strategies in the form of disability-adjusted life-years 
(DALYs) averted, a measure that captures the extent to 
which the interventions reduce the premature death and 
ill-health caused by a disease, including, in the HIV 
Synthesis model, reductions in morbidity and mortality 
from the prevention of onward HIV transmission.5,6 
DALYs averted for all scenarios run by each model are 
presented in the appendix. In our scenarios, 1 life-year in 
perfect health receives a weight of 0, whereas 1 life-year 
lived with a WHO stage 3 or 4 event (developed on the 
basis of viral load monitoring, CD4 cell count, and failure 
or absence of antiretroviral therapy) receives a substantial 
weight (0·547), and 1 life-year lived with asymptomatic 
HIV (eg, on successful antiretroviral therapy) receives a 
moderate weight of 0·053, portraying the decrement in 
the quality of life from these conditions.12,13 We estimated 
DALYs averted by applying DALY-weights to years lived 
and clinical events generated by the models, and not 
through estimating total burden of disease in the 
countries. Both costs and outcomes are discounted to 
2012 present value in US dollars using a 3% discount rate.14
Economic analyses
The expected costs and health outcomes (DALYs averted) 
associated with each of the monitoring alternatives can 
be compared to inform which is likely to represent the 
best value from available resources.14,15 We ranked the 
strategies by eﬀ ectiveness, removing those less eﬀ ective 
and more costly than an alternative (ie, subject to 
dominance) or a linear combination of alternatives 
(subject to extended dominance). We compared all 
remaining strategies using incremental cost-eﬀ ectiveness 
ratios (ICERs), showing the additional cost per unit of 
health gain (DALY averted) from a strategy compared 
with the next most eﬀ ective alternative. ICERs are 
represented graphically in the form of cost-eﬀ ectiveness 
frontiers that connect those strategies that provide the 
greatest health returns at any given cost.
Threshold for switching Abbreviation Frequency of monitoring Monitoring strategy included in the model
HIV Synthesis Braithwaite Estill
No monitoring None (no switching) NS None (no monitoring) Implemented* Implemented* Implemented*
Clinical monitoring WHO stage 4 event CM, S4 Every 6 months Implemented* Implemented* No
Clinical monitoring WHO stage 3 or 4 event CM, S3/4 Every 6 months Implemented* No Implemented*
Clinical monitoring 
and CD4 cell count
CD4 <100 cells per μL or new 
stage 4 event
CD4 <100/S4 Every 6 months Implemented* No No
CD4 cell count CD4 cell count below baseline 
or <50% of peak value on ART
CD4-CA Every 6 months Implemented* Implemented* Implemented*
CD4 cell count and 
viral load monitoring
CD4 cell count below baseline 
or <50% of peak value on ART; 
VL ≥1000 copies per mL
CD4/TGVL Every 6 months (CD4 
count—VL only done if CD4 
failure)
Implemented* Implemented* Implemented*
Clinical monitoring 
plus CD4 cell count 
plus viral load 
monitoring
New stage 4 event; or CD4 cell 
count below baseline or <50% 
of peak value on ART; or viral 
load ≥1000 copies per mL
CD4/TGVL+ Every 6 months (Clinical 
monitoring plus TGVL); 
every 12 months (routine 
viral load monitoring)
Implemented* No No
Viral load monitoring 1000 copies per mL VL12 Every 12 months Implemented* Implemented* Implemented*
Viral load monitoring 1000 copies per mL VL36 Every 36 months Implemented* No Implemented*
Viral load monitoring 500 copies per mL VL6/VL ≥500 Every 6 months No No
Viral load monitoring 1000 copies per mL VL6 Every 6 months Implemented* Implemented* Implemented*
Viral load monitoring 5000 copies per mL VL6/VL ≥5000 Every 6 months Implemented* No No
Viral load monitoring 10 000 copies per mL VL6/VL ≥10 000 Every 6 months Implemented* Implemented* No
TGVL=targeted viral load. ART=antiretroviral therapy. CA=current algorithm. *Scenario was implemented in corresponding model.
Table 2: Monitoring strategies modelled, by abbreviation
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Importantly, ICERs alone cannot show which strategy is 
likely to be most appropriate for a particular setting: this 
requires comparison with a cost-eﬀ ectiveness threshold. 
The appropriate threshold in a particular setting depends 
on the opportunity costs of committing resources to fund 
an intervention, measured in terms of the health gains 
foregone because of displacement of alternative 
interventions that would not then be provided. An 
intervention can therefore only be deemed cost eﬀ ective if 
the health gains that the intervention generates exceed 
what would have been gained if that intervention was not 
adopted and the resources were deployed elsewhere.
Opportunity costs themselves depend on the decision 
context and how else resources could be spent. In 
situations where scale-up of antiretroviral therapy is not 
complete, opportunity costs might include health gains 
from the provision of antiretroviral therapy using lower-
cost monitoring approaches to those in need who are not 
currently receiving treatment. We therefore compared 
patient monitoring results with estimates of the cost 
eﬀ ectiveness of antiretroviral therapy to infer the value-
for-money of monitoring alternatives (ie, we compared 
the health beneﬁ ts of money spent on monitoring with 
money spent on expanding antiretroviral therapy).
Sensitivity analyses investigate how results change 
with lower testing costs (as might be expected with the 
arrival of point-of-care or other new technologies) and 
reduced second-line antiretroviral drugs costs. These are 
presented in the form of incremental net monetary 
beneﬁ t (I-NMB), of routine viral load monitoring 
compared with the best monitoring alternative at a 
particular cost-eﬀ ectiveness threshold. I-NMB is a 
measure of the value of health gains, on a monetarised 
scale, resulting from an intervention compared with the 
health gains that could be realised if the resources 
required to fund that intervention were used for 
alternative purposes.15 A positive I-NMB for routine viral 
load monitoring therefore indicates it is cost eﬀ ective 
compared with other monitoring alternatives at a given 
cost-eﬀ ectiveness threshold, whereas a negative I-NMB 
indicates the health gains are not large enough relative to 
costs to recommend its adoption.
Role of the funding source
WHO authors contributed to the design of the study, the 
selection of settings considered and strategies evaluated, 
but had no role in the development or selection of 
epidemiological models, the conduct of the analyses, or 
in ter pretation of results. The Bill & Melinda Gates 
Foundation had no role in the design of the analysis, 
interpretation of the results, or the decision to submit the 
manuscript for publication. The corresponding author 
had ﬁ nal responsibility for the decision to submit for 
publication.
Results
The ICERs per DALY averted for each strategy are 
presented for Zambia in ﬁ gure 1. Signiﬁ cantly, the 
results from Malawi and South Africa were in precise 
qualitative agreement in that the ranking of each 
Figure 1: Cost-eﬀ ectiveness frontier plots for Zambia (ICERs per DALY 
averted, 2012 US$)
DALY=disability-adjusted life-year. (A) Estill model. (B) Braithwaite model. 
(C) HIV Synthesis model. The frontier line that represents a most eﬃ  cient pathway 
of spending as resources increase is shown in red together with the ICERs—ie, the 
incremental cost per DALY averted of moving from one strategy to the next along 
the frontier. NS=no monitoring and no switching. VL6=viral load monitoring 
every 6 months. VL12=viral load monitoring every 12 months. VL36=viral load 
monitoring every 36 months. CM S3/4=clinical monitoring with switching on a 
new WHO stage 3 or 4 event. CD4-CA=clinical monitoring plus CD4 monitoring, 
switching at fall of CD4 cell count below baseline or of 50% or more from peak 
value on treatment. CD4/TGVL=targeted viral load strategy (viral load is used to 
conﬁ rm a suspected failure based on immunological criteria). >500=switching at 
>500 copies per mL. >5K=switching at >5000 copies per mL. >10K=switching at 
>10 000 copies per mL. CD4<100/S4=switching at <100 cells per μL or new 
stage 4 event. *Dominated or extendedly dominated strategies.
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scenario along the cost frontier is the same across the 
three countries (appendix).
All models show that no monitoring and no switching 
(ie, maintaining one line of antiretroviral therapy) is 
the least costly and least eﬀ ective strategy in the base 
case analyses. Viral load monitoring every 6 months 
(VL6) is the most costly and most eﬀ ective alternative 
in every model; viral load monitoring every 12 months 
(VL12, switching at >1000 copies per mL) is the next-
most-eﬀ ective strategy in all models and is also slightly 
less costly.
Clinical and CD4-based monitoring approaches 
represent intermediate alternatives in cost and eﬀ ective-
ness in all models (ﬁ gure 1). In the HIV Synthesis model, 
clinical monitoring (switching on a new WHO stage 3 or 
4 event [CM S3/4]) oﬀ ers notable beneﬁ ts at low incre-
mental costs compared with no monitoring and no 
switching. The addition of CD4 monitoring (CD4-CA) to 
clinical monitoring alone confers a beneﬁ t particularly in 
the HIV Synthesis and Braithwaite models, at an 
incremental cost meaning that it might be aﬀ ordable in 
more settings than regular viral load monitoring. The 
Braithwaite results lend support to a targeted viral load 
strategy (CD4/TGVL, whereby a viral load is used to 
conﬁ rm a suspected failure based on immunological 
criteria), which might be considered as a stepping stone 
towards the routine use of viral load monitoring—perhaps 
as programmes wait for cheaper point-of-care viral load 
monitoring to become widely available. This strategy 
would be less likely to be favoured, however, if it meant 
new viral load laboratory infrastructure had to be built or 
if it led to viral load machines being used at low volume 
and higher unit costs. Furthermore, we note that CD4-CA 
lies very close to the frontier in the Braithwaite model.
To assess whether improvements in patient monitoring 
should be prioritised over expanded coverage of 
antiretroviral therapy, we ran the Braithwaite model using 
costs from Malawi. We assumed that the antiretroviral 
therapy coverage (ie, the proportion of people eligible for 
antiretroviral therapy who are receiving it) was currently 
50%, and that clinical monitoring was used for patients 
on antiretroviral therapy. In these respects, the model 
represents the situation in many eastern and southern 
African countries, where despite recommendations for 
CD4 or viral load monitoring being in place, scale-up of 
these strategies is limited and clinical monitoring 
remains widespread (median antiretroviral therapy 
coverage level noted in east and southern Africa is 56%16).
We considered a situation in which an HIV/AIDS 
programme has a choice between investing additional 
resources in routine 6-monthly viral load monitoring 
(while maintaining antiretroviral therapy coverage at 
50%), or in increasing antiretroviral therapy coverage 
from 50% while still using clinical monitoring. In this 
hypothetical example, increasing antiretroviral therapy 
coverage—rather than upgrading patient monitoring—
would be expected to generate much greater health 
beneﬁ ts (ﬁ gure 2). This result is consistent with the 
enormous beneﬁ ts of antiretroviral therapy for patients 
with CD4 cell count of about 350 cells per μL compared 
with not receiving antiretroviral therapy at all, and the 
relatively modest beneﬁ ts associated with the more 
extensive patient monitoring strategies in all the models 
(ﬁ gure 1).
Other studies have also estimated that health gains for 
introducing antiretroviral therapy with clinical monitoring 
compared with no antiretroviral therapy can be realised at 
much lower ICERs than we estimate for the introduction 
of CD4 and viral load monitoring (Braithwaite, 2011, 
estimates an ICER of $600 per quality-adjusted life-year 
[QALY] gained for two lines of antiretroviral therapy with 
clinical monitoring and no ﬁ xed assumptions on the 
number of regimens available versus no antiretroviral 
Figure 2: Costs and beneﬁ ts (DALYS averted) of alternative uses of resources 
(Braithwaite model) 
DALY=disability-adjusted life-year. ART=antiretroviral therapy. Results are per 
100 000 HIV-infected individuals with both beneﬁ ts and costs estimated over a 
20 year budgeting horizon and discounted at 3% per annum.
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therapy, which is similar to previous published estimates 
of $590 per life-year gained,17 and $628 per QALY gained 
with one line of antiretroviral therapy only18).
In some other settings with high antiretroviral therapy 
coverage using CD4 monitoring, such as Zambia, the 
relevant policy choice would seem to be whether to spend 
additional resources on the provision of viral load 
monitoring or increasing the antiretroviral therapy 
eligibility criteria to CD4 cell count lower than 500 cells 
per μL. An additional analysis was run in the Braithwaite 
model to examine these alternatives (ﬁ gure 3). The 
ﬁ ndings suggest that earlier initiation of antiretroviral 
therapy, while still using CD4 monitoring, would cost 
less and generate greater health gains than would 
keeping the threshold of antiretroviral therapy initiation 
at 350 cells per μL and using viral load monitoring. This 
ﬁ nding is also indicated in the low ICERs (less than 
$290 per DALY averted in Zambia) that have recently 
been reported for earlier antiretroviral therapy initiation 
in those already in care.19
To assess the sensitivity of our results to particular cost 
assumptions, and to examine how results might change 
in response to changing costs, we constructed two 
alternative scenarios: (1) reduced costs of second-line 
antiretroviral regimens, with second-line costing the same 
as average current ﬁ rst-line antiretroviral regimen costs; 
and (2) reduced costs of providing assays, which might be 
expected with the development of new CD4 cell count and 
viral load technologies, including point of care tests, of 
$4 per test for CD4 cell count and $10 per test for viral load 
monitoring (compared with the $9·50 per test for CD4 cell 
count and $45 per test for viral load monitoring used in 
the original analyses shown in ﬁ gure 1).
Figure 4 shows the I-NMB associated with routine 
12-monthly viral load monitoring compared with the best 
non-routine viral load monitoring strategy.14,15 The I-NMB 
of routine viral load monitoring can be interpreted as the 
diﬀ erence in the value of health gains generated from 
routine viral load monitoring and the value of health 
gains foregone as a result of those resources required to 
fund this monitoring strategy being unavailable to deliver 
other interventions, at particular cost-eﬀ ectiveness 
threshold levels. At higher cost-eﬀ ectiveness thresholds, 
resources buy fewer health gains elsewhere in the health-
care system and therefore the I-NMB of routine viral load 
monitoring increases. This might be the case, for 
instance, if a country has full antiretroviral therapy 
coverage and few other opportunities to generate health 
gains at low cost. However, at lower cost-eﬀ ectiveness 
thresholds, the higher costs of routine viral load 
monitoring are of greater consequence because they 
displace investments in interventions that could oﬀ er 
health gains at low cost.
Reduced second-line costs and reduced testing costs 
would make 12-monthly viral load cost eﬀ ective at lower 
cost-eﬀ ectiveness thresholds than under base case 
assumptions (marked by where the lines cross the x-axis). 
However, the magnitude of these eﬀ ects varies somewhat 
across the models. In the HIV Synthesis model, reduced 
second-line costs had very little eﬀ ect on the cost 
eﬀ ectiveness of routine viral load monitoring, but when 
the costs of the tests themselves fall, routine viral load 
monitoring becomes cost eﬀ ective at a much lower 
threshold. In the Braithwaite and Estill models, 
reductions in the costs of second-line treatment were 
Figure 4: Scenario analyses
I-NMB=incremental net monetary beneﬁ t. POC=point of care. ICER=incremental 
cost-eﬀ ectiveness ratio. ART=antiretroviral therapy. The ﬁ gures show the I-NMB 
of 12-monthly routine viral load monitoring compared with the best alternative 
non-routine viral load strategy at a given cost-eﬀ ectiveness threshold. A positive 
value of I-NMB implies that 12-monthly viral load monitoring (vertical axis) is 
cost eﬀ ective at a particular cost-eﬀ ectiveness threshold (horizontal axis), 
whereas a negative I-NMB indicates it is not cost eﬀ ective because the 
opportunity costs exceed the health gains the intervention oﬀ ers. Routine viral 
load monitoring becomes “cost eﬀ ective” under each scenario at the threshold 
where the I-NMB line crosses the horizontal axis. 
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more important for the cost eﬀ ectiveness of viral load 
monitoring. However, in all models, the combination of 
reducing second-line cost and reduction in test costs 
makes it much more likely that viral load monitoring 
would be cost eﬀ ective.
Discussion
This analysis shows that a limited availability of resources 
to monitor patients should not be a barrier to scale-up of 
antiretroviral therapy. We ﬁ nd that expanding treatment 
to more patients at existing thresholds for antiretroviral 
therapy initiation, or initiating antiretroviral therapy at 
higher CD4 cell counts while using clinical or 
immunological monitoring, would be a more eﬀ ective 
use of resources than investing in more extensive patient 
monitoring using viral load tests. However, we also ﬁ nd 
that viral load monitoring would confer additional 
beneﬁ ts to patients and populations, especially over the 
long term, and that if the cost of viral load monitoring 
falls substantially, then it might become a cost-eﬀ ective 
strategy in future, particularly in settings with high 
antiretroviral therapy coverage (panel).
A major strength of this analysis is that it draws on 
various independent models, which come to very similar 
conclusions. This provides reassurance that the 
conclusions are robust to diﬀ erent ways in which the 
disease progression and monitoring can be represented 
in models. Although we have not provided results for the 
models across ranges of assumptions for adherence, 
delays in switching patients, and other factors, we know 
of no data that suggest these issues would interfere with 
the overall conclusions we have drawn about the relative 
priorities of the diﬀ erent strategies. We have not explicitly 
presented the impact of monitoring on HIV drug 
resistance or HIV transmission, but we emphasise that 
this is included in two of the models presented (table 1) 
and its eﬀ ects are captured in the aggregate estimate of 
impact. Furthermore, it is possible that, by parameterising 
the models on the basis of trial data, the models 
overestimate the eﬀ ect of monitoring compared with 
what would happen in real programmes. There is no 
reason to believe, however, that this would systematically 
bias our result to favouring one strategy over another, 
although there would be great beneﬁ t in evaluating the 
performance of these alternative strategies in routine 
programmes to test this assumption.
The systematic nature of our compiled analysis has 
aﬀ orded insights into the underlying reasons for the 
models to give slightly diﬀ erent results in some cases. 
Particularly, in the HIV Synthesis model, CD4 
monitoring strategies perform better relative to other 
strategies than is the case in the two other models. This 
diﬀ erence seems to be because, in that model, the 
proportion of life-years lived with immunological 
failure where there is also virological failure (at 
>1000 copies per mL) is higher than in the Braithwaite 
model (and higher than the proportion of concurrent 
failures [as episodes, not life-years lived] in the Estill 
model). It is also higher than some reports in the 
literature of the positive predictive values of CD4 failure 
for virological failure, although these studies are based 
largely on people who initiated ART fairly recently, and 
the correlation between virological and immunological 
failure may increase with time on ART.32–39 Thus, in the 
HIV Synthesis model, the CD4 information is assumed 
to be a more reliable guide to viral failure than 
elsewhere, reducing the marginal gains in health from 
using viral load monitoring in that model.
Other published models besides the three used here 
have also examined optimal strategies for antiretroviral 
therapy monitoring, in a range of settings, and have 
ﬁ ndings that are consistent with our results.5,9,20 One 
model, however, stands in contrast: Hamers and 
colleagues10 previously suggested that viral load monitoring 
would be cost-saving and could improve life-expectancy. 
Panel: Research in context
Systematic Review
We searched PubMed, Medline, and Google Scholar for modelling studies published 
between Sept 15, 2007, and Sept 15, 2012, with search terms “viral load monitoring”, 
“patient monitoring”, “cost-eﬀ ectiveness”, “mathematical modelling”, “antiretroviral 
therapy”, “modelling patient monitoring”, and “HIV treatment monitoring.” A list of 
studies reviewed (including some before Sept 15, 2007) is shown in the appendix.
Patient monitoring models were last reviewed in 2010.20 Mathematical models that have 
attempted to represent disease progression and monitoring are consistent with trial and 
observational data: immunological monitoring oﬀ ers some morbidity and mortality 
beneﬁ t (ie, less time spent with clinical events, fewer deaths) over clinical monitoring, and 
virological monitoring might oﬀ er some morbidity and mortality beneﬁ t over 
immunological monitoring.4–8,11 Two randomised controlled trials have found that routine 
CD4 monitoring reduces patient morbidity and mortality relative to clinical monitoring 
alone.21–23 Several studies have evaluated the added eﬀ ect of viral load monitoring 
compared with CD4 or clinical monitoring, but have not found major eﬀ ects on morbidity 
or mortality.21,22,24–27 However, compared with CD4 monitoring21,24 or clinical monitoring,26,27 
routine CD4 and viral load monitoring led to more patient switching to second-line drugs. 
Routine use of viral load was found to lead to more frequent switches to second-line 
drugs, compared with use of viral load only to conﬁ rm a failure based on clinical or 
immunological criteria.25 It has also been suggested that viral load monitoring (and by 
implication, targeted viral load for conﬁ rmation of immunological failure) might prevent 
unnecessary switches to second-line therapy in patients who are failing clinically or 
immunologically but not virologically.28 Less time spent with non-suppressed viral load 
could reduce the development of resistance5,28,29 and the onward transmission of HIV;5,30,31 
however, Laurent and colleagues26,27 found no diﬀ erence in the proportion of resistance in 
the clinical and laboratory arms, and Jourdain and colleagues23 found just one case with 
resistance mutations in the CD4 arm.
Interpretation
Drawing overarching conclusions from existing patient monitoring models is 
complicated by models’ use of diﬀ erent cost inputs and heterogeneity in strategies 
modelled. Our analysis shows that three models brought together and run on a core set of 
scenarios with the same costs come to largely similar conclusions. It also conﬁ rms that 
these modelling results are largely consistent with the trial literature, and over a longer 
timeframe than the trial data.
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resources, the relatively modest anticipated beneﬁ t of 
viral load monitoring is worth the added cost, and 
whether the opportunity costs in morbidity and mortality 
of forgoing the use of these resources for other eﬀ orts is 
acceptable. We show here that routine viral load 
monitoring at current cost might be appropriate only in 
wealthier countries, especially those that have scaled-up 
to close-to-full antiretroviral therapy coverage, or if the 
cost of viral load testing were to fall considerably.
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